EGFR and adenocarcinoma: LCINS patients with adenocarcinoma frequently carry mutations within the tyrosine kinase domain of the EGFR gene, whereas smokers tend to have KRAS mutations and are associated with resistance to EGFR-TKI, thus emphasising the need for classification of mutational status, prior to targeted therapy studies and clinical trials, to provide guidance for the preferred treatment route.